Compare Manchester United PLC (MANU) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manchester United PLC vs Merck & Co., Inc. — how do they compare? Manchester United PLC trades at $22.71 (market cap $3.80B), while Merck & Co., Inc. trades at $133.95 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 84.7× Manchester United PLC's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| MANU | MRK | |
|---|---|---|
Market Cap | $3.80B | $321.77B |
Sector | Media | Health |
52-Week High | $23.53 | $131.84 |
52-Week Low | $15.10 | $77.60 |
Enterprise Value | $4.74B | $368.53B |
Dividend Yield | 1.26% | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manchester United (MANU) trades at $22.60, up 4.15% today, with a bearish technical signal. The company reported Q1 2026 EPS of $0.04, beating expectations, but missed in Q4 2025. Revenue trends show modest growth to $667M in 2025, though net income remains negative. Key developments include securing land for a new stadium and Champions League qualification boosting future revenue prospects.
The outlook is mixed; stadium development and cost reductions offer long-term upside, but persistent losses and high debt pose risks. Analysts are cautious with 40% buy ratings. Investment opportunity hinges on operational turnaround, while risks include weak cash flow and competitive pressures.
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
